David Venables has been appointed to the board of Ark Therapeutics as executive director of manufacturing services. He reports to chief executive Martyn Williams.
Venables joins Ark from Intercell, an international vaccines company, where he has been responsible since 2007 for building manufacturing capabilities in Europe and the US, most recently, as chief operating officer of Intercell USA, based in Maryland.
Prior to joining Intercell, Venables was director of operations at BioReliance Europe, and before that director of market development and global manufacturing at Invitrogen.
Williams commented: ‘David’s extensive experience in building commercially focused manufacturing service businesses will enable us to accelerate the development of our viral manufacturing capability into a self-sustaining business.’
Ark Therapeutics Group is a gene-based medicine company with operations in the UK and Finland. The firm’s research is focused on discovering new approaches to gene delivery using viral vectors with particular emphasis on genes that control tissue vascularisation, especially VEGF.
